As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.
16 Analysts have issued a Cullinan Oncology Inc forecast:
16 Analysts have issued a Cullinan Oncology Inc forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -209 -209 |
22%
22%
|
EBIT (Operating Income) EBIT | -209 -209 |
22%
22%
|
Net Profit | -179 -179 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Cullinan Oncology, Inc. is a biopharmaceutical company engages in developing oncology and immuno-oncology therapies. The company was founded by Patrick R. Baeuerle on 15 September, 2016 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Nadim Ahmed |
Employees | 85 |
Founded | 2016 |
Website | cullinantherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.